An unidentified 79-year-old patient gained access to the experimental obesity drug retatrutide through the FDA’s compassionate use pathway, according to reports from STAT News and The New Republic. While speculation persists regarding the patient’s identity, federal agencies have declined to confirm if the individual is former President Donald Trump. The drug was requested in April by Dr. Ranganath Muniyappa, a senior clinician at the National Institutes of Health (NIH), to treat severe obesity, sleep apnea, and pulmonary hypertension.
How does the FDA compassionate use pathway work?
The FDA’s compassionate use program, formally known as Expanded Access, allows patients with serious or life-threatening conditions to access medical products that have not yet been approved for general market use. According to the FDA, each request is evaluated on an individual basis to determine if the potential benefits outweigh the risks. The patient must demonstrate that no comparable or satisfactory alternative therapy exists. In this instance, records cited by The New Republic indicate the patient had previously used tirzepatide with limited success and was not considered a suitable candidate for weight-loss surgery.
The FDA grants thousands of compassionate use requests annually, but access to experimental drugs like retatrutide—which is still in clinical trials—is significantly more restricted than access to drugs already approved for other conditions.
Why is the use of retatrutide significant?
Retatrutide is an investigational drug currently being developed by Eli Lilly. Unlike existing treatments, it is designed to target three different hormone receptors—GLP-1, GIP, and glucagon—to promote weight loss. Clinical trials for the drug are ongoing. The involvement of an NIH clinician in the request highlights the high level of medical oversight required for such experimental interventions. While STAT News queried the White House regarding the patient’s identity, a spokesperson referred all inquiries to the Department of Health and Human Services, which maintains a policy of not disclosing individual patient identities.
What are the regulatory precedents for high-profile access?
There is a historical contrast between how the public perceives access to experimental medicine and the regulatory reality of the Expanded Access program. While the program is designed for patients who have “exhausted all other options,” high-profile individuals often face intense scrutiny when they utilize these pathways. According to STAT News, the request for this specific patient was filed while the drug was still in the midst of its development cycle, underscoring the urgency of the patient’s reported health conditions: severe obesity, sleep apnea, and pulmonary hypertension.
Pro Tip: Tracking Drug Development
If you are interested in the progress of experimental obesity medications, you can track clinical trial status and FDA status updates directly through the ClinicalTrials.gov database. This resource provides real-time data on active studies for drugs like retatrutide.
Frequently Asked Questions
- Can anyone apply for compassionate use? No. A physician must submit the request to the FDA and the pharmaceutical manufacturer, who must both agree to provide the drug.
- Is retatrutide FDA-approved? No. As of the most recent reports, it remains an experimental drug undergoing clinical trial evaluation.
- Why was this specific patient granted access? According to documentation cited by The New Republic, the patient was deemed a poor candidate for surgery and showed limited success with other, already-approved obesity treatments.
What are your thoughts on how experimental drugs are distributed? Join the conversation in the comments below or subscribe to our health policy newsletter for ongoing updates on pharmaceutical regulations.
